Clinical Trial: Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793475) titled 'Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease' on Jan. 21.

Brief Summary: This is a prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of aponermin-based bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma patients with extramedullary disease.

Study Start Date: Jan., 2025

Study Type: INTERVENTIONAL

Condition: Extramedullary Multiple Myeloma

Intervention: BIOLOGICAL: anti-BCMA/GPRC5D bispecific CAR-T

Autologous BCMA/GPRC5D bispecific CAR-T cells, infusion intravenously at ...